Literature DB >> 15802325

Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.

Terhi Piltonen1, Laure Morin-Papunen, Riitta Koivunen, Antti Perheentupa, Aimo Ruokonen, Juha S Tapanainen.   

Abstract

BACKGROUND: Anti-Müllerian hormone (AMH) is secreted by granulosa cells of ovarian early developing follicles and its serum levels have been shown to correlate with small antral follicle number. Since the pronounced androgen secretion from follicles/stroma in women with polycystic ovary syndrome (PCOS) remains until late reproductive age, and since AMH reflects the number of antral follicles, it was of interest to study the possible age-related relationship between AMH, androgens and follicle number in women with PCOS and in control women. Moreover, the possible effect of metformin on serum AMH levels and the relationship to follicle count and volume were studied.
METHODS: Forty-four healthy women (aged 21-44 years) and 65 women with previously diagnosed PCOS (aged 16-44 years) participated in the study. Serum basal AMH levels were correlated with those of serum androstenedione, testosterone, estradiol (E2), LH, FSH and inhibin B, and with follicle number. The effect of metformin on serum AMH concentrations, follicle number and ovarian volume was studied in 26 women (aged 20-41 years) with PCOS after 6 months of treatment.
RESULTS: Serum AMH levels were 2- to 3- fold higher in PCOS women than in healthy women. In control women, serum AMH levels correlated positively with those of serum androstenedione (r = 0.564, P < 0.001) and testosterone (r = 0.328, P = 0.036) and negatively with serum FSH concentrations (r = -0.374, P = 0.012) and age (r = -0.691, P<0.001). In women with PCOS, serum AMH levels correlated positively with those of androstenedione (r = 0.311, P = 0.011) and testosterone (r = 0.310, P = 0.011) and with follicle count (r = 0.352, P = 0.012), and negatively with age (r = -0.300, P = 0.014). Serum AMH levels, the number of antral follicles and ovarian volume decreased significantly during metfromin treatment.
CONCLUSIONS: Serum AMH levels decreased with age both in healthy women and in women with PCOS, although they were always 2- to 3-fold higher and remained elevated until 40 years of age in PCOS subjects. Thus, since serum AMH levels correlate well with antral follicle count and serum androgen levels, the measurement of AMH could be used as a tool to assess ovarian ageing, to diagnose polycystic ovaries/PCOS and to evaluate treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802325     DOI: 10.1093/humrep/deh850

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  56 in total

1.  Anti mullerian hormone: a potential marker for recruited non growing follicle of ovarian pool in women with polycystic ovarian syndrome.

Authors:  P Saikumar; Vs Kalai Selvi; K Prabhu; Prasana Venkatesh; Prashanth Krishna
Journal:  J Clin Diagn Res       Date:  2013-09-10

2.  First assessment of menstrual cycle function and reproductive endocrine status in Samoan women.

Authors:  G Lambert-Messerlian; M B Roberts; S S Urlacher; J Ah-Ching; S Viali; M Urbanek; S T McGarvey
Journal:  Hum Reprod       Date:  2011-06-15       Impact factor: 6.918

3.  Serum antimüllerian hormone in healthy premenopausal women.

Authors:  Christiana M Shaw; Frank Z Stanczyk; Brian L Egleston; L L Kahle; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

4.  Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.

Authors:  Annie A Guedikian; Alexandria Y Lee; Tristan R Grogan; David H Abbott; Karla Largaespada; Gregorio D Chazenbalk; Daniel A Dumesic
Journal:  Fertil Steril       Date:  2018-02-07       Impact factor: 7.329

5.  Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.

Authors:  Melissa Pawelczak; Lisa Kenigsberg; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

6.  Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer.

Authors:  Daniel A Dumesic; Timothy G Lesnick; Jacques P Stassart; G David Ball; Ashley Wong; David H Abbott
Journal:  Fertil Steril       Date:  2009-07       Impact factor: 7.329

7.  Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin.

Authors:  Angela Falbo; Morena Rocca; Tiziana Russo; Antonietta D'Ettore; Achille Tolino; Fulvio Zullo; Francesco Orio; Stefano Palomba
Journal:  J Ovarian Res       Date:  2010-07-21       Impact factor: 4.234

Review 8.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

9.  Assay reproducibility and within-person variation of Müllerian inhibiting substance.

Authors:  Joanne F Dorgan; Cynthia S Spittle; Brian L Egleston; Christiana M Shaw; Lisa L Kahle; Louise A Brinton
Journal:  Fertil Steril       Date:  2009-05-05       Impact factor: 7.329

10.  Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.

Authors:  Joanne F Dorgan; Frank Z Stanczyk; Brian L Egleston; Lisa L Kahle; Christiana M Shaw; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2009-10-09       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.